Loading...

Heinzerling, Keith Gregory

Title(s)Associate Professor-in-Residence, Family Medicine
Phone(310) 319-4700
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Phase 1 safety-interaction study of pomaglumetad methionil for methamphetamine use disorder
    NIH/NIDA R01DA043238Sep 15, 2016 - Jul 31, 2019
    Role: Principal Investigator
    Randomized Trial of Ibudilast for Methamphetamine Dependence
    NIH/NIDA R01DA035054Aug 15, 2012 - Feb 28, 2018
    Role: Principal Investigator
    Pilot Trial of Bupropion versus Placebo for Methamphetamine Abuse in Adolescents
    NIH/NIDA R21DA026513Apr 15, 2009 - Feb 28, 2012
    Role: Principal Investigator
    Pharmacogenomics and Medication Development for Methamphetamine Dependence
    NIH/NIDA K23DA023558Apr 1, 2008 - Mar 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Young SD, Lee SJ, Perez H, Gill N, Gelberg L, Heinzerling K. Social media as an emerging tool for reducing prescription opioid misuse risk factors. Heliyon. 2020 Mar; 6(3):e03471. PMID: 32181385.
      View in: PubMed
    2. Quinn B, Gorbach PM, Okafor CN, Heinzerling KG, Shoptaw S. Investigating possible syndemic relationships between structural and drug use factors, sexual HIV transmission and viral load among men of colour who have sex with men in Los Angeles County. Drug Alcohol Rev. 2020 02; 39(2):116-127. PMID: 32012373.
      View in: PubMed
    3. Heinzerling KG, Briones M, Thames AD, Hinkin CH, Zhu T, Wu YN, Shoptaw SJ. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. J Neuroimmune Pharmacol. 2019 Dec 09. PMID: 31820289.
      View in: PubMed
    4. Li MJ, Briones MS, Heinzerling KG, Kalmin MM, Shoptaw SJ. Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder. Drug Alcohol Depend. 2020 Jan 01; 206:107776. PMID: 31812878.
      View in: PubMed
    5. Young SD, Koussa M, Lee SJ, Perez H, Gill N, Gelberg L, Heinzerling K. Feasibility of a social media/online community support group intervention among chronic pain patients on opioid therapy. J Addict Dis. 2018 Jan-Jun; 37(1-2):96-101. PMID: 30614403.
      View in: PubMed
    6. Worley MJ, Swanson AN, Heinzerling KG, Roache DJO, Shoptaw S. Corrigendum to "Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study" [Drug Alcohol Depend. 162 (2016) 245-250]. Drug Alcohol Depend. 2018 09 01; 190:120. PMID: 30014886.
      View in: PubMed
    7. Briones M, Shoptaw S, Cook R, Worley M, Swanson AN, Moody DE, Fang WB, Tsuang J, Furst B, Heinzerling K. Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial. Drug Alcohol Depend. 2018 Aug 01; 189:30-36. PMID: 29860057.
      View in: PubMed
    8. Severino AL, Shadfar A, Hakimian JK, Crane O, Singh G, Heinzerling K, Walwyn WM. Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic. Front Psychiatry. 2018; 9:119. PMID: 29740351.
      View in: PubMed
    9. Ober AJ, Watkins KE, Hunter SB, Ewing B, Lamp K, Lind M, Becker K, Heinzerling K, Osilla KC, Diamant AL, Setodji CM. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study. BMC Fam Pract. 2017 12 21; 18(1):107. PMID: 29268702.
      View in: PubMed
    10. Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla KC, Hunter SB, McCullough CM, Becker K, Iyiewuare PO, Diamant A, Heinzerling K, Pincus HA. Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT Randomized Clinical Trial. JAMA Intern Med. 2017 10 01; 177(10):1480-1488. PMID: 28846769.
      View in: PubMed
    11. Bachtell RK, Jones JD, Heinzerling KG, Beardsley PM, Comer SD. Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend. 2017 11 01; 180:156-170. PMID: 28892721.
      View in: PubMed
    12. Birath JB, Briones M, Amaya S, Shoptaw S, Swanson AN, Tsuang J, Furst B, Heinzerling K, Obermeit L, Maes L, McKay C, Wright MJ. Ibudilast may improve attention during early abstinence from methamphetamine. Drug Alcohol Depend. 2017 09 01; 178:386-390. PMID: 28704767.
      View in: PubMed
    13. Worley MJ, Heinzerling KG, Shoptaw S, Ling W. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction. 2017 Jul; 112(7):1202-1209. PMID: 28164407.
      View in: PubMed
    14. Cook R, Quinn B, Heinzerling K, Shoptaw S. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. Addiction. 2017 Jun; 112(6):1077-1085. PMID: 28107598.
      View in: PubMed
    15. Young SD, Heinzerling K. The Harnessing Online Peer Education (HOPE) Intervention for Reducing Prescription Drug Abuse: A Qualitative Study. J Subst Use. 2017; 22(6):592-596. PMID: 29551953.
      View in: PubMed
    16. Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology. 2017 Aug; 42(9):1776-1788. PMID: 28091532.
      View in: PubMed
    17. Watkins KE, Ober AJ, Lamp K, Lind M, Diamant A, Osilla KC, Heinzerling K, Hunter SB, Pincus HA. Implementing the Chronic Care Model for Opioid and Alcohol Use Disorders in Primary Care. Prog Community Health Partnersh. 2017; 11(4):397-407. PMID: 29332853.
      View in: PubMed
    18. DeYoung DZ, Heinzerling KG, Swanson AN, Tsuang J, Furst BA, Yi Y, Wu YN, Moody DE, Andrenyak DM, Shoptaw SJ. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. J Clin Psychopharmacol. 2016 Aug; 36(4):347-54. PMID: 27269956.
      View in: PubMed
    19. Worley MJ, Swanson A-N, Heinzerling KG, Roche DJ, Shoptaw S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016 05 01; 162:245-50. PMID: 26993372.
      View in: PubMed
    20. Heinzerling KG, Demirdjian L, Wu Y, Shoptaw S. Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder. J Psychiatr Res. 2016 Mar; 74:22-9. PMID: 26736037.
      View in: PubMed
    21. Worley MJ, Heinzerling KG, Shoptaw S, Ling W. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. Exp Clin Psychopharmacol. 2015 Dec; 23(6):428-35. PMID: 26302337.
      View in: PubMed
    22. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shoptaw S, Heinzerling K, London ED, Miotto K. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Neuropsychopharmacology. 2015 Sep; 40(10):2347-56. PMID: 25801501.
      View in: PubMed
    23. Heinzerling KG, Swanson AN, Hall TM, Yi Y, Wu Y, Shoptaw SJ. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction. 2014 Nov; 109(11):1878-86. PMID: 24894963.
      View in: PubMed
    24. Ray LA, Roche DJ, Heinzerling K, Shoptaw S. Opportunities for the development of neuroimmune therapies in addiction. Int Rev Neurobiol. 2014; 118:381-401. PMID: 25175870.
      View in: PubMed
    25. Swanson AN, Shoptaw S, Heinzerling KG, Wade AC, Worley M, McCracken J, Wilson SA, Asarnow J, London ED. Up in smoke? A preliminary open-label trial of nicotine replacement therapy and cognitive behavioral motivational enhancement for smoking cessation among youth in Los Angeles. Subst Use Misuse. 2013 Dec; 48(14):1553-62. PMID: 23822739.
      View in: PubMed
    26. Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev. 2013 Sep; 32(5):449-60. PMID: 23617468.
      View in: PubMed
    27. Heinzerling KG, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health. 2013 Apr; 52(4):502-5. PMID: 23333007.
      View in: PubMed
    28. Brensilver M, Heinzerling KG, Swanson AN, Shoptaw SJ. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. Exp Clin Psychopharmacol. 2012 Oct; 20(5):430-5. PMID: 22867036.
      View in: PubMed
    29. Brensilver M, Heinzerling KG, Swanson AN, Shoptaw SJ. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend. 2012 Sep 01; 125(1-2):169-72. PMID: 22534658.
      View in: PubMed
    30. Heinzerling KG, Shoptaw S. Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use. Gend Med. 2012 Apr; 9(2):112-20. PMID: 22445683.
      View in: PubMed
    31. Brensilver M, Heinzerling KG, Swanson AN, Telesca D, Furst BA, Shoptaw SJ. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev. 2013 Jan; 32(1):96-9. PMID: 22385210.
      View in: PubMed
    32. Heinzerling KG, McCracken JT, Swanson AN, Ray LA, Shoptaw SJ. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol. 2012 Feb; 32(1):135-7. PMID: 22217949.
      View in: PubMed
    33. Ling W, Shoptaw S, Hillhouse M, Bholat MA, Charuvastra C, Heinzerling K, Chim D, Annon J, Dowling PT, Doraimani G. Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction. 2012 Feb; 107(2):361-9. PMID: 22082089.
      View in: PubMed
    34. Heslin KC, Stein JA, Heinzerling KG, Pan D, Magladry C, Hays RD. Clinical correlates of health-related quality of life among opioid-dependent patients. Qual Life Res. 2011 Oct; 20(8):1205-13. PMID: 21328090.
      View in: PubMed
    35. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010 Jun 01; 109(1-3):20-9. PMID: 20092966.
      View in: PubMed
    36. De La Garza R, Zorick T, Heinzerling KG, Nusinowitz S, London ED, Shoptaw S, Moody DE, Newton TF. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacol Biochem Behav. 2009 Nov; 94(1):186-93. PMID: 19698734.
      View in: PubMed
    37. Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, Kalechstein AD, Shoptaw S. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):48-55. PMID: 19608354.
      View in: PubMed
    38. Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009 Apr 15; (2):CD003021. PMID: 19370579.
      View in: PubMed
    39. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, De La Garza R, Newton T, Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008 Aug 01; 96(3):222-32. PMID: 18468815.
      View in: PubMed
    40. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang PC, Bholat MA, Ling W. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis. 2008; 27(1):13-23. PMID: 18551884.
      View in: PubMed
    41. Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008 Feb; 98(2):278-83. PMID: 17538068.
      View in: PubMed
    42. Heinzerling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. J Subst Abuse Treat. 2007 Jun; 32(4):423-9. PMID: 17481466.
      View in: PubMed
    43. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Dec 01; 85(3):177-84. PMID: 16740370.
      View in: PubMed
    44. Heinzerling KG, Etzioni DA, Hurley B, Holtom P, Bluthenthal RN, Asch SM. Hospital utilization for injection drug use-related soft tissue infections in urban versus rural counties in California. J Urban Health. 2006 Mar; 83(2):176-81. PMID: 16736367.
      View in: PubMed
    45. Heinzerling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. Unmet need for recommended preventive health services among clients of California syringe exchange programs: implications for quality improvement. Drug Alcohol Depend. 2006 Feb 01; 81(2):167-78. PMID: 16043308.
      View in: PubMed